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DEK is important in regulating cellular processes including proliferation, differentiation andmaintenance of stem
cell phenotype. The translocation t(6;9) in Acute Myeloid Leukemia (AML), which fuses DEK with NUP214, con-
fers a poor prognosis and a higher risk of relapse. The over-expression of DEK in AML has been reported, but dif-
ferent studies have shown diminished levels in pediatric and promyelocytic leukemias. This study has
characterized DEK expression, in silico, using a large multi-center cohort of leukemic and normal control cases.
Overall, DEK was under-expressed in AML compared to normal bonemarrow (NBM). Studying speciﬁc subtypes
of AML conﬁrmed either no signiﬁcant change or a signiﬁcant reduction in DEK expression compared to NBM.
Importantly, the similarity of DEK expression between AML and NBMwas conﬁrmed using immunohistochem-
istry analysis of tissue mircorarrays. In addition, stratiﬁcation of AML patients based on median DEK expression
levels indicated that DEK showed no effect on the overall survival of patients. DEK expression during normal he-
matopoiesis did reveal a relationshipwith speciﬁc cell types implicating a distinct function duringmyeloid differ-
entiation. Whilst DEK may play a potential role in hematopoiesis, it remains to be established whether it is
important for leukemagenesis, except when involved in the t(6;9) translocation.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).
Introduction
Acute Myeloid Leukemia (AML) is primarily a hematological
malignancy of the elderly with a median age of onset at 60 years and a
poor prognosis with a ﬁve year survival rate of only 12% [1]. It is
characterized by the accumulation of immature myeloblasts as a conse-
quence of arrested myeloid differentiation and a subsequent deﬁciency
in functional mature granulocytes and monocytes. AML often arises
from chromosomal translocations resulting in speciﬁc leukemia-
associated fusion proteins. These chimeric gene products exhibit
distinctive functions that impede upon normal cellular proliferation
and/or differentiation and are utilized to classify AML into speciﬁc sub-
types and risk groups of favorable, intermediate and adverse. The rare
translocation t(6;9), present in 1–5% of AML cases [2], results in the pro-
duction of the DEK-NUP214 (formerly CAN) fusion, which is associated
with a particularly poor prognosis and a median age of 44 years at diag-
nosis. The DEK oncogene was originally identiﬁed from this leukemic
translocation, where the 5′ portion of the DEK gene located on chromo-
some 6p23was fused to the 3′ region of the NUP214 gene found on chro-
mosome 9q34 resulting in the 165 kDa DEK-NUP214 fusion [3]. The
leukemogenic potential of the DEK-NUP214 protein was undecided as it
was unable to completely block differentiation of hematopoietic progen-
itors [4]. Subsequent data fromOancea et al. indicatedDEK-NUP214 could
promote leukemic transformation of a subset of long term repopulating
hematopoietic stem cells [5], clearly pointing to an important contribu-
tion of DEK-NUP214 to leukemia. Data from two studies have revealed
that the expression of DEK-NUP214may increase the overall protein pro-
duction by targeting translation [6], and may additionally accelerate pro-
liferation through up-regulation of the mTOR pathway [7]. A recent
international multicenter study has concluded that DEK-NUP214 repre-
sents a unique subtype of AML accompanied by increased risk of relapse,
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higher FMS-like tyrosine kinase 3 internal tamdemdulpication (FLT3 ITD)
mutation frequency and a deﬁned gene signature [8]. However, the
precise molecular function of this fusion gene and its disease
contribution remain mostly elusive.
HumanDEK, 43 kDa in size, is an abundant and primarily chromatin-
associated nuclear factor [9]. DEK exhibits a wide variety of molecular
functions (e.g. regulation of gene expression, RNA biology, DNA repair,
apoptosis, senescence, and chromatin structure), suggesting that it is
critically involved in a myriad of cellular processes that relate to
proliferation, differentiation, senescence and the maintenance of cell
stemness [10]. Currently, it is believed that these functions are predom-
inantly transmitted by the architectural functions of DEKwithin cellular
DNA and chromatin [10]. DEK has two distinct DNA-binding domains
(SAP-box and C-terminal DNA binding domain), which can induce
intra- and intermolecular contacts that lead to the alteration of DNA
and chromatin topology [11–13]. It is thought that changes to cellular
DEK levels are most likely involved in regulating genomic stability and
gene expression through concerted action of epigenetic mechanisms
and chromatin architectural functions [10].
Although DEK predominately localizes in the nucleus under steady-
state conditions, induced DNA damage, apoptosis and pro-inﬂammatory
environments lead to its presence in the extracellular space, either
through passive release in apoptosis by T-cells or active secretion from
macrophages [14–16]. Extracellular DEK, in turn, gains novel functions,
exhibiting chemo-attractant properties, resulting in the attraction of cer-
tain immune cells such as leukocytes of the immune system to the site of
inﬂammation [15,16]. It has been shown recently by the addition of exog-
enous recombinant DEK that it can also mediate functions of hematopoi-
etic stem cells (HSC) by suppressing proliferation of hematopoietic
progenitor cells (HPC) and enhancing engraftment of long term
repopulating cells [17,18]. Interestingly, DEK added to cells is taken up
in a bioactive form, moved to the nucleus and re-engages in its bona
ﬁde chromatin functions, thus suggesting the existence of a paracrine-
loop-like mechanism [19]. Furthermore, DEK works in concert with the
transcription factor C/EBPα, whose function can be impaired in AML [20].
DEK also has a long-standing and well-established association
with oncogenesis, as it is consistently over-expressed in a number of
prevalent and hard-to-treat neoplasms (e.g. retinoblastoma, glioblasto-
ma,melanoma and prostate cancer) [21]. HighDEK expression has been
shown to directly promote cellular transformation through bypassing
major barriers to early oncogenesis and tumor maintenance such as
apoptosis and senescence, thus establishing DEK as a bona ﬁde
oncogene [22–26]. Furthermore, its expression correlates with meta-
stases and notorious chemoresistance of melanoma and other cancers
[22,24,27].
Besides the expression of the DEK-NUP214 fusion gene, two
previous studies have indicated that DEK itself is over-expressed in
AML [28,29]. In one study, DEK expression proﬁling was analyzed at
diagnosis of 15 primary AML patients with normal and complex
karyotypes [28] and quantitative reverse transcription -PCR (qRT-
PCR) suggested that DEK was over-expressed independently of karyo-
type in nine of these cases (60%). Similarly, a qRT-PCR approach
showed DEK over-expression in 98% of cases from a cohort of 41 AML
patients. Higher levels of DEK were associated with CD34 negative
bone marrow samples and independent of the t(6;9) chromosomal
translocation [29]. Conversely, DEK expression has been found to be di-
minished in pediatric AML in comparison to normal bone marrow [26].
In addition, a study of 14 acute promyelocytic leukemia (APL) patients
harboring the t(15:17) translocation revealed a non-signiﬁcant four-
fold down-regulation of DEK expression [30]. Overall there are conﬂict-
ing data regarding the expression status of DEK in AML patients both
with or without the t(6;9) translocation.
Although aberrant expression of DEK has been associated with AML,
its role in the development of leukemia independent of the t(6;9) trans-
location remains largely unknown. Previously, DEK expression was
reported to be 10-fold lower inmature hematopoietic cells as compared
to immature CD34 positive cells [6]. Since four studies analyzing DEK
expression in leukemia were inconclusive the aim of this study was to
characterize DEK expression in a large multi-center cohort of AML
cases. As an initial reference, DEK expression was proﬁled during
normal hematopoietic differentiation of the myeloid lineage in both
human and mouse using the Hemaexplorer database [31]. Analysis of
DEK expression in primary AML samples was compared to normal
bone marrow using both the Microarray Innovations in Leukemia
(MILE) study [32] and acute myeloid leukemia dataset (LAML) from
Ley et al [33] andmapped back to the normal hematopoietic expression.
This was validated and conﬁrmed in independent cohorts of primary
AML patient samples at the RNA level by qRT-PCR and at the protein
level by immunohistochemistry using a newly assembled AML-
speciﬁc tissuemicroarray (TMA). Finally, DEK expressionwas evaluated
in relation to overall survival of AML patients and prognostic relevance
using the LAML dataset [33].
Materials & methods
DEK expression proﬁling in normal hematopoiesis
DEK expression during normal hematopoiesis in both human and
murinemodels was assessed using the publicly available Hemaexplorer
database (http://servers.binf.ku.dk/hemaexplorer) [31], which enabled
DEK gene expression levels to be proﬁled in hematopoietic cells during
different maturation stages based on curated microarray data. The
data was analyzed using the Partek Genomics Suite v 6.6 (Partek Inc.,
Missouri, USA) and GraphPad Prism 5 (GraphPad, California, USA). All
data was normalized and batch corrected.
DEK expression proﬁling in AML
DEK expression levels in AML compared to normal bone marrow
(NBM) were determined using the Affymetrix CEL ﬁles generated for
the MILE study database GSE13204 [32] and the LAML dataset [33],
and analyzed using Partek Genomics Suite v 6.6. ANOVA was carried
out on microarray results by comparing DEK expression in NBM con-
trols to leukemia in addition to comparison tests betweenNBMand spe-
ciﬁc AML subtypes. Overall patient survival associated with DEK
expression was analyzed using the alternative microarray dataset
LAML generated as part of The Cancer Genome Atlas (TCGA; [33]).
Reverse transcription and quantitative PCR
RNA was extracted and puriﬁed from samples of 30 patients with
AML (OREC 08/NIR01/9). Synthesis of cDNA was performed using the
High-Capacity cDNA reverse transcription (RT) kit according to the
manufacturer's protocol (Applied Biosystems, California, USA). RT was
performed using the Veriti Thermal Cycler (Applied Biosystems) at the
following conditions: 25 °C for 10 min, 37 °C for 2 h, 85 °C for 5 min
and a 4 °C hold period. All qRT-PCR was executed using the SYBR
green mastermix (Roche) on the 7900HT Fast Real-time PCR platform
(Applied Biosystems) with standard cycling conditions (95 °C for
10 min followed by 40 cycles of 95 °C for 10 s and 60 °C for 30 s). The
following primers were used to analyze DEKmRNA expression levels:
DEK forward primer ACGGAACAGTTCTGGAATGG and DEK reverse
primer TTTTGGTGGCTCCTCTTCAC.
Immunohistochemistry procedures
In total 122 AML cases (57 female, 65 male with an average age of
60 years) and age-matched bone marrow samples from tumor-free
NBMwere used to build TMAs, utilizing a semi-automated tissue array-
er (TMArrayer, Pathology Devices, Westminster, MD, USA). The donor
tissues were archived bone marrow biopsies and were included in this
study using pseudonymized numbers, including tumor entity, gender,
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and age with the permission of the ethical review committee of the
RTWH Aachen University. Archived parafﬁn blocks were used and re-
cipient parafﬁn blocks were heated for 4 h at 40 °C to prevent cracks
and missing cores. Subsequently, 3 μm sections were produced and
dried overnight. Immunohistochemical staining was performed by
using a heat induced antigen retrieval method in citrate buffer (pH6)
(DAKO, Carpinteria, CA; USA), followed by blocking of endogenous per-
oxidase activity by hydrogen peroxide solution (3%) and blocking of
unspeciﬁc protein binding sites (milk powder, 1%). The primary an-
tibody (monoclonal DEK antibody, BD Transduction Laboratories,
610948) with a dilution of 1:400 was incubated on the slides for
1 hour. After washing, the biotinylated secondary antibody was in-
cubated for 30 min followed by the strepatavidin–horseradish
peroxidase complex (30 min) and chromogene (DAB, 3 min),
which were components of the LSAB+-Kit (DAKO, Carpinteria, CA,
USA). Slides were counterstained with hematoxylin and dehydrated
Fig. 1. Differential DEK expression during human hematopoiesis. A. Dot plot representing relative DEK expression during the maturation process of normal human hematopoiesis from
immatureHSC tomature cell types inmyeloid and lymphoid lineages using theHemaexplorer database. B. (i) Radar plot indicating differential DEK expression throughoutmyeloid speciﬁc
normal hematopoietic differentiation. Each radius represents a particular hematopoietic cell stage. (ii) Bar chart highlightingDEK expression duringnormal humandifferentiation from the
common myeloid cells towards the granulocytic (G) and monocytic (M) lineages. *** p b 0.001 and ** p b 0.01. C. Comparison of DEK expression in HSC, common progenitors, mature
granulocytes andmaturemonocytes between normal human andmurinemodels of hematopoiesis. All values represent relativemRNA expression levels. Abbreviations as follows: hema-
topoietic stem cell (HSC), hematopoietic progenitor cell (HPC), commonmyeloid progenitor (CMP), granulocytemonocyte progenitor (GMP),megakaryocyte erythroid progenitor (MEP),
promyelocyte (PM), myelocyte (MY), polymononuclear cells (PMN), natural killer cells (NK) and dendritic cells (DC).
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before the addition of coverslips. The stainingwas scored by an expe-
rienced pathologist (T.B) as an overall staining intensity (staining,
numbers of cells) using a semi-quantitative scale, 0–3 in 0.5
increments.
Statistical analysis
Two-way ANOVA or Student t-tests were performed on all data
using GraphPad Prism 5 software (GraphPad, California, USA). Differ-
ences of p b 0.001 (***) indicate strong statistical signiﬁcance, p b 0.01
(**) signiﬁcant, p b 0.05 (*) a weak statistical signiﬁcance and p N 0.05
(n.s.) denotes no statistical signiﬁcance.
Results
DEK expression during normal hematopoiesis
As a crucial prerequisite for the analysis of potentially altered DEK
expression in AML samples,weﬁrst characterized the expression proﬁle
across normal hematopoietic differentiation. A comprehensive in silico
analysis of human hematopoietic cells revealed that DEK expres-
sion was elevated in immature HSCs and diminished markedly in
mature myeloid cells present in the peripheral blood and bone
marrow (Fig. 1A). DEK expression decreased in a steady stepwise
progression in the myeloid lineage with the lowest DEK levels ob-
served in mature cells of the granulocyte lineage, predominantly
the polymononuclear cells (PMNs), which exhibited a seven-fold
lower expression as compared to immature HSCs (p b 0.001)
(Fig. 1Bi & ii). Although both granulocytes and monocytes exhibit-
ed a reduced level of DEK as compared to HSCs, monocytes were
found to express three-fold more DEK compared to normal
granulocytes (p b 0.01) (Fig. 1Bii).
It is unknown if the DEK expression proﬁle we observed during
human hematopoietic differentiation is similar to that of other species,
such as mice; a commonly used model. The function of DEK in HSCs
has previously been partially elucidated in murine models but the
expression proﬁle during murine hematopoietic differentiation has
not been characterized. Thus an in silico analysis of murine hematopoi-
etic stem cells and progenitors was carried out and compared to that of
human hematopoiesis. Dek expression was found to increase from
immature long term HSCs (LT-HSCs), reaching a peak at the common
progenitor stage namely the granulocyte monocyte progenitor (GMP)
before diminishing below its initial expression levels in the mature,
terminally differentiated cells (Supplementary Fig. 1A & B). This was
in contrast to normal human hematopoiesis, which displayed a decline
with no peak in expression at the common progenitor stage. In the
myeloid lineages there was a steady incline of Dek expression in
common myeloid cells during normal murine hematopoiesis, with a
three-fold increase in Dek expression at the GMP cell stage relative to
HSCs (p b 0.001). However, compared to the LT-HSCs, Dek expression
dropped to a three and two-fold lower level in mature granulocytes
and monocytes respectively, (Supplementary Fig. 1Bi and ii). Compari-
son of DEK levels in mature myeloid cells indicated a small difference
of 1.5-fold between granulocytes and monocytes, with granulocytes
exhibiting higher DEK expression (Supplementary Fig. 1Bii). Analysis
of DEK expression at different stages during myeloid differentiation in
human and murine cells revealed signiﬁcant differences at the
GMP and granulocyte stages, while levels in monocytes were similar
(Fig. 1C).
DEK expression levels are reduced in AML
To determine if the expression of DEK in AML was aberrant
compared to normal hematopoietic differentiation, DEK levels in un-
fractionated bone marrow derived from 542 AML patients and 74
normal controls were analyzed using the MILE study. A lower, yet not
signiﬁcant, DEK expression across all AML subgroups combined was
seen as compared to NBM (Fig. 2A). Since a previous study had already
indicated that the APL subgroup of AML exhibited lower DEK expres-
sion, theMILE datawas further categorized into different AML subtypes,
as available, andDEK expression re-analyzed. As observed in theunsort-
ed AML cases, elevated DEK expressionwas not found in any of the AML
subtypes as compared to NBM(Fig. 2Bi). In contrast, all subtypes includ-
ing 11q23 translocations, normal and other cytogenetics as well
as those with balanced recurrent translocations of t(8;21), and
t(15;17) displayed signiﬁcantly reduced DEK expression compared to
NBM (p b 0.005) with the exception of inv(16) (Fig. 2Bi & Table 1).
These ﬁndings were further conﬁrmed in a second AML dataset [33],
which showed similarly reduced DEK expression levels across all AML
subtypes as compared to those in the MILE dataset (Fig. 2Bii). This
data was ﬁnally compared to AML data from the Hemaexplorer data-
base. DEK was found to exhibit a comparable or reduced level of
expression to the common promyelocyte stage of normal myeloid dif-
ferentiation, which is indicative of immature myeloblasts that accumu-
late in leukemia (Supplementary Fig. 2). Furthermore, when levels of
DEK expression were normalized to that of myeloblasts (equivalent to
the closest normal counterpart of myeloid cells), DEK was signiﬁcantly
under-expressed in AML, as indicated by a relative mean value less
than 1, which was particularly prominent in the APL sub-type (Fig. 2C).
Expression proﬁling of primary AML samples conﬁrms that DEK is not over-
expressed in AML
This section and Fig. 3 should be in the main text of the Results Sec-
tion after “DEK expression levels are reduced in AML”. To validate the in
silico results, we measured DEK expression by qRT-PCR in a separate
and independent cohort of deﬁned primary AML samples. Patient char-
acteristics of this primary AML sample cohort are outlined in Supple-
mentary Table 1. DEK expression was found to be similar in 30 AML
samples and the 5 NBM, with no signiﬁcant change in the ΔCt between
NBMand AML observed (Fig. 3A). To establish if DEK expressionwas in-
dependent of varying AML subtypes, samples were further divided into
the following subgroups: normal karyotype, promyelocytic leukemia
(chromosomal translocation t(15;17)), core binding factor leukemia
(chromosomal aberrations t(18;21) and inv(16)), and others, which in-
cluded 11q23 translocations and complex karyotypes. DEK expression
remained similar across all AML subgroups with no signiﬁcant change
in expression between each AML subtype when compared to each
other or between individual subtypes and NBM (Fig. 3B).
DEK protein levels are low in AML bone marrow
AlthoughDEKmRNA levelswere reduced or remainedunchanged it is
possible that this does not correlate with protein levels as little is known
Fig. 2. DEK expression levels are under-expressed in AML.A. Box andwhisker plot comparing the expression of DEK between normal bonemarrow (NBM, n=74) (green) and acute my-
eloid leukemia (AML, n= 542) (red) using the MILE study database. Y-axis represents log2 expression levels. B. (i) Box and whisker plots comparing DEK expression levels of AML sub-
types (11q23, complex, Normal, Other, inv(16), t(15;17) and t(8;21)) to NBM using theMILE study database. Y-axis represents log2 expression and p-values are outlined in Table 1. *** p
b 0.001 comparingAML subtypes to NBM(green). (ii) Box andwhisker plots comparingDEK expression levels between AML subtypes (Complex cytogenetics, Normal cytogenetics, Other,
inv(16), t(15;17) and t(8;21)) using the LAML study database. Y-axis represents log2 expression. C. Hemaexplorer dot plot depicting DEK expression levels in AML compared to
promyelocytes considered as the closest normal counterpart. Greydashed lines represent DEKexpression closest to normal counterpart innormal hematopoiesiswith a relative expression
value of 1. Samples exhibiting DEK over-expression are indicated by the red arrow and a relative expression greater than 1while samples displaying reduced levels of DEK are represented
by the blue arrow with a relative expression lower than 1.
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about the post-transcriptional cues that regulate DEK mRNA. Since we
were particularly interested to validate our ﬁndings at the protein level
a novel custom-built TMAwas assembled. The TMAutilized bonemarrow
biopsies from 122 AML patients and 20 age-matched bone marrow sam-
ples from tumor-free normal bone marrow, which were allocated from
the Biobank at the University Clinic of the RWTH Aachen University. All
samples were spotted in triplicate, including appropriate positive and
negative controls, to produceﬁve TMA slides in total. The slideswere sub-
jected to immunohistochemistry using a monoclonal DEK-speciﬁc anti-
body (Fig. 4). We observed a strong DEK-speciﬁc nuclear signal in a
colon biopsy, which served as a positive control for the speciﬁcity of the
antibody (Fig. 4A-1). In contrast, the DEK antibody produced a rather
weak, diffusely cytoplasmic staining, which was seen mainly in myeloid
progenitor cells, in 90% of normal bone marrow biopsies from tumor-
free patients (Fig. 4A-2 and B). The majority of AML samples presented
with a similar outcome of none or weak nuclear staining with mostly
none (score 0) (Fig. 4A-3 and B) or weak (score 0.5) (Fig. 4A-4 and B)
DEK staining as determined by pathology assessment. Around 10% of
the AML biopsies showed a moderate staining (score 1, Fig. 4A-5 and
B), and only less than 5% of all AML samples exhibited a strong nuclear
staining (score 2; Fig. 4A-6 and B). Thus, DEK expression at the protein
level was in agreement with the data obtained at the mRNA level in the
other AML cohorts.
Reduced DEK expression does not inﬂuence overall survival of AML patients
Since overall reduced andparallel expression of DEK both at the RNA
and protein level was found in AML, it is possible that DEK may have
prognostic relevance for the long term survival of AML patients. Using
leukemia microarray datasets 164 patients with DEK expression were
stratiﬁed into four equal quartiles of 40 patients with Quartile 1
exhibiting the lowest DEK expression and Quartile 4 representing the
highest DEK expression (Table 2). Overall survival of patients in each
quartile was independent of DEK expression (Supplementary Fig. 3Ai).
Additionally, Kaplan–Meier curves plotting DEK expression above and
below the median indicated that the overall survival of patients was
identical regardless of low or high DEK levels (Supplementary
Fig. 3Bi). The Kaplan–Meier curves show that Quartiles 1–3 combined
exhibited an increased, but insigniﬁcant survival beneﬁt compared to
those patients in Quartile 4 with the highest DEK expression levels
(Fig. 5A). Based upon the long term survival of AML patients it is
possible to divide AML into 3 risk groups, favorable, intermediate and
adverse. Although all quartile groups contained patients from each
risk group, the favorable risk group patients were more prevalent in
Quartiles 1 and 2 while the remaining quartiles are mainly composed
of the intermediate risk group (Table 2). Removing the favorable risk
group from the analysiswhich includes patients harboring the recurrent
balanced translocations including t(15;17), t(8;21) and inv(16), and re-
plotting the Kaplan–Meier curves resulted in identical long term
survival between high (Quartile 4) and low levels (combined Quartiles
1–3) of DEK expression (Fig. 5B). Similarly, no difference in overall
survival was observed with removing the favorable risk group from
the individual quartiles or when comparing DEK expression above and
below the median levels (Supplementary Fig. 3 A&Bii respectively).
The favorable group, which can be treated with all-trans retinoic
acid (ATRA), contains the acute promyelocytic leukemia patients with
Fig. 3.DEK expression proﬁling inprimary AML samples. A. qRT-PCR analysis of DEK expression in 30primary AML patient samples compared to 5 unfractionatedNBMcontrols B. qRT-PCR
analysis comparingDEKmRNAexpression levels in unfractionatedNBMto primary AML samples subdivided into differentAML subtypes including normal karyotypen=7,promyelocytic
leukemia (t(15;17) n= 12, core binding factor leukemias (t(8;21) and inv(16)) n= 5 and other (11q23 and complex) n= 6. Y-axis of both plots represents ΔCt whereby high ΔCt in-
dicates low expression levels and low ΔCt translates to high expression levels. 18S was used as an endogenous control.
Table 1
Summary of signiﬁcantly reduced DEK expression in AML.
Comparison of DEK expression levels in AML subtypes (11q23, complex cytogenetics, Normal karyotype, Other, inv(16), t(15;17) and t(8;21)) to NBMusing theMILE study database. Data
summarized by median expression similar to NBM or median expression lower than that of unfractionated NBM. p-values indicated in ﬁnal column.
NBM vs subtype DEK expression change compared to NBM p-value
Favorable inv (16) Similar expression to NBM 0.099
t(15;17) Median expression lower than NBM 6.042 e − 6
t(8;21) Median expression lower than NBM 1.231 e − 5
Intermediate Normal karyotype Median expression lower than NBM 0.004
Other Median expression lower than NBM 0.001
11q23 Median expression lower than NBM 0.001
Adverse Complex karyotype Similar expression to NBM 0.023
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translocation t(15;17) and core binding factor aberrations including
translocation t(8;21) and inv(16). Thus it appears that DEK expression
does not inﬂuence patient survival independent of the favorable risk
group of AML patients.
Discussion
In this report, DEK expression was comprehensively analyzed during
normal human hematopoietic differentiation for the ﬁrst time. DEK
expression was found to be the highest in human hematopoietic stem
cells but decreased during myeloid differentiation up to 7-fold in
granulocytes (Fig. 1). This broadly agreed with the detection of a 10-
fold lower expression of DEK in mature cells from peripheral blood
compared to normal CD34+ cells as revealed in a previous study
[6]. However, not all terminally differentiated cells from different hema-
topoietic lineages exhibited similar expression of DEK, as higher DEK
levels were observed in lymphoid cells as compared to mature myeloid
cells. Within themyeloid lineage, monocytes had a 3-fold higher DEK ex-
pression than granulocytes (Fig. 1). Since DEK could be important in reg-
ulating granulocytic differentiation it may be expected that its expression
could subsequently promote terminal differentiation in AML. In contrast,
mice exhibited amarkedly different expression pattern compared to that
of humans (Fig. 1C & Supplementary Fig. 1). Most signiﬁcantly, murine
cells expressed elevated levels of Dek in GMPs and mature granulocytes
as compared to the humanmyeloid cell equivalent (p b 0.001). However,
DEK expression levels in monocytes were similar (Fig. 1C). Overall, dis-
tinct DEK expression patterns were observed during the progression of
normal hematopoiesis, with DEK levels substantially reduced in mature
cells compared to HSCs. Thus it appears that DEK levels during murine
and human hematopoiesis highlight potential differences which may re-
ﬂect cell type speciﬁc functions of DEK. However, the precise function of
DEK in myeloid proliferation/differentiation remains unknown and re-
quires further elucidation.
Since DEK is generally found up-regulated inmultiple humanmalig-
nancies and is associated with the AML subgroup harboring the t(6:9)
translocation it is possible that AML may also exhibit up-regulated
DEK. However, four previous studies analyzing DEK expression in AML
have given discordant results with over-expression in two studies and
either no signiﬁcant change or decreased expression in the others.
Consequently this study aimed to clarify the expression status of DEK
in AML. Analysis of DEK expression in three datasets of AML patients
indicated that DEK was not over-expressed and may actually be
under-expressed in the majority of cases. Furthermore, dividing the
AML patients into different subtypes detected no signiﬁcant change or
decreased DEK expression (Fig. 2). In agreement with our ﬁndings, a
previous study of 14 APL cases, whichpossess the t(15;17) translocation
and have a favorable prognosis, showed that there was no signiﬁcant
change in DEK expression. Analysis of over 500 pediatric AML samples
from theOncomine dataset [26], combinedwith over 600 adult samples
in the MILE and LAML studies plus collated microarrays from the
Hemaexplorer dataset, totalingmore than 1000 cases of AML, supported
an association of reduced DEK expression in AML. Although themedian
DEK expression was normal or reduced there was a range of expression
levels with a few highly expressed outliers (Fig. 2 & Supplementary
Fig. 2). Importantly, this observed pattern of reduced DEK expression
was also seen at the protein level using a distinctively different AML
Fig. 4. DEK protein expression is also diminished in AML. A. Immunohistochemistry analysis of a custom-built AML TMA. Shown are representative micrographs. 1: colon biopsy with
strongly DEK-speciﬁc nuclear staining; 2: normal bone marrow from tumor free patients with very weak and diffuse DEK staining; 3–6: AML samples with no DEK staining (3: score
0); weak DEK staining (4: score 0.5); moderate DEK staining (5: score 1) and strong DEK staining (6: score 2). Magniﬁcation 400×. B. Bar chart depicting percentage of NBM tumour-
free and AML patients for each category of DEK stain distribution .
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cohort that was analyzed by immunohistochemistry on newly created
AML TMAs. Also, low levels of DEK expression were observed in
most AML blasts, with only a few high DEK expression outliers, fully in
agreement with the RNA expression data from the MILE, LAML and
Hemaexplorer. Reduced DEK expression does not appear to be associat-
ed solely with pediatric leukemia as previously suggested, supported
by the inclusion of exclusively adult cases investigated throughout this
study in all datasets and primary AML patient samples. Patients
included represent a comprehensive range of AML subtypes and low
DEK expression was found to be associated with all AML subtypes,
which was veriﬁed in an independent cohort of primary samples
(Fig. 2).
Low DEK expression may be of prognostic relevance for the long
term survival of AML patients but stratifying patients on the basis of
DEK expression levels indicated that there was no inﬂuence on patient
survival either in the presence of absence of the favorable risk group
of AML patients (Fig. 5 & Supplementary Fig. 3). The favorable group
contains patients with APL, who have a good prognosis as ATRA treat-
ment alleviates the block in differentiation. It is unknown whether
DEK contributes to improved survival in the favorable risk group
although in the study of APL patients Savli et al. [30], similarly to our
study, found that DEK expression was reduced by a factor of 4 but this
was not statistically signiﬁcant. However, there is insufﬁcient evidence
to establish if DEK levels may have an effect on overall survival of the
favorable risk group patients, especially those classiﬁed as promyelocytic.
Based on the gene expression levels of DEKexpression it canbe concluded
that DEK does not correlate with the survival of AML patients.
In this study we investigated the expression of the DEK oncogene in
three independent AML datasets and, contrary to current perception,
established that DEK is under-expressed compared to the equivalent
normal myeloid cell. However, DEK did not inﬂuence overall survival
of AML patients. DEK levels in normal hematopoietic differentiation of
human and mouse revealed that DEK levels were associated with HPC
and speciﬁc cell stages, hence suggesting distinct functions during
myeloid differentiation for DEK. Although the precise function of DEK
in myeloid proliferation and differentiation remains unknown, DEK
may be playing an important role in hematopoiesis. However, it remains
to be established whether DEK is important for leukemagenesis, except
when involved in the t(6;9) translocation.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bcmd.2014.07.009.
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